Recursion Pharmaceuticals Reports Q2 2023 Net Loss of $76.7 Million

Recursion Pharmaceuticals, Inc.(RXRX) has released its financial results f or the second quarter of 2023, revealing a net loss of $76.7 million. The company also reported total revenue of $11.0 million for the same period. These figures reflect the performance and financial health of the company during the first half of the year.

Net Loss of $76.7 Million Marks Q2 2023 Performance

Recursion Pharmaceuticals, a pioneering biotechnology company, disclosed a net loss of $76.7 million for the second quarter of 2023. This loss is in comparison to the net loss of $65.6 million reported during the same period in the previous year. The company attributes this loss to various factors including operating costs, expenses, and investments in research and development activities. The net loss per share of Class A, B, and Exchangeable common stock was reported as $0.38 for the quarter, compared to the same figure in the prior year.

Q2 2023 Revenue Reaches $11.0 Million